The Supreme Court's decision in Monsanto Co. v. Durnell, No. 24-1068, handed down in June 2026, closed the primary litigation pathway that had driven the Roundup glyphosate cancer docket for nearly a decade. In a 7-2 ruling authored by Justice Kavanaugh, the Court held that FIFRA's express preemption provision, 7 U.S.C. § 136v(b), bars state-law failure-to-warn claims that would require a pesticide label different from or in addition to the EPA-approved label. Roughly 60,000 to 65,000 pending Roundup cases face the question of what, if anything, survives that holding.
The Holding and Its Scope
FIFRA Section 136v(b) provides that states may not impose or continue in effect any requirements for labeling or packaging of pesticides in addition to or different from what FIFRA requires. The Durnell plaintiffs, users of Roundup who developed non-Hodgkin lymphoma, argued that glyphosate's link to cancer constituted a failure by Monsanto to provide adequate warnings under state tort law. Bayer and Monsanto countered that the EPA had evaluated glyphosate and repeatedly concluded that the existing Roundup label was adequate and that no cancer warning was required, making any state-law claim that the label was deficient an impermissible attempt to impose a requirement different from the EPA's determination.
The majority agreed. It held that when EPA has made a definitive labeling determination, state tort law cannot demand a different warning. The practical effect is that failure-to-warn claims, the theory underlying the vast majority of the Roundup docket, are preempted if they rest on the absence of a cancer warning. The two dissenters, Justices Gorsuch and Jackson, argued that the preemption clause was not intended to immunize manufacturers from liability when the regulatory approval was based on incomplete science.
What Claims Survive Durnell
The FIFRA preemption ruling is not total. The Court's holding is specifically directed at failure-to-warn claims predicated on labeling inadequacy. Three categories of claims may survive:
- Design defect: A claim that glyphosate itself, as formulated, is unreasonably dangerous regardless of labeling is not a labeling claim. Design defect theory under the risk-utility test or the consumer expectation test challenges the product formulation, not the label. The Durnell majority did not address whether FIFRA preempts design defect claims, and at least one federal circuit has held it does not.
- Manufacturing defect: A claim that a specific batch of Roundup was contaminated or deviated from the intended formula is similarly not a labeling claim and should survive preemption.
- Parallel state claims: Under the parallel claim doctrine developed in the medical device preemption context, a state-law claim that tracks a specific FIFRA violation, rather than imposes an obligation beyond FIFRA, is not preempted. If EPA's own regulations required a safety study that Monsanto failed to conduct, and the failure resulted in an incorrect label, a claim based on that regulatory violation may not be preempted under Durnell.
The practical challenge is that failure-to-warn was the primary revenue theory in the Roundup docket. Design defect claims require different expert testimony, different causation proof, and a different damages model. Plaintiff firms currently holding Roundup cases should audit their dockets against the specific theory pled in each complaint and evaluate whether a viable non-labeling claim exists for each client before the preemption defense eliminates the case entirely.
The $7.25 Billion Class Settlement and the Remaining Opt-Outs
Prior to the Durnell ruling, a Missouri court granted preliminary approval to Bayer's proposed $7.25 billion settlement covering existing and future Roundup claimants. The settlement had a June 2026 opt-out deadline. Claimants who opted out to pursue independent litigation now face the Durnell ruling as a threshold obstacle if their claims rest on failure-to-warn.
For claimants who accepted the class settlement before Durnell, the terms presumably bind. For opt-outs, the strategic picture shifted materially the moment the ruling issued. The opt-out plaintiff's attorney must assess whether design defect or parallel-claim theories are viable in the specific client's case, or whether the preemption ruling effectively moots the individual claim. In cases where the claimant is elderly, in poor health, or unable to sustain prolonged litigation, settlement under the class framework may remain the better option even now, particularly if Bayer maintains a claims administration process for late-joining class members.
Broader Implications for Agricultural and Consumer Pesticide Litigation
Durnell's reach extends beyond glyphosate. FIFRA governs all pesticide products registered with the EPA, including herbicides, insecticides, and fungicides used in agriculture, commercial pest control, and consumer lawn care products. Any existing litigation or potential claim that rests on a pesticide's failure to warn of health hazards that the EPA has evaluated and declined to require a warning for is now presumptively preempted under the Durnell framework.
This affects an array of cases that were building on the Roundup litigation model: claims against chlorpyrifos-containing products, claims against certain fumigants and fungicides used in agricultural settings, and consumer product claims about termiticide and rodenticide exposure. Plaintiff counsel in these cases must identify non-labeling theories or evaluate parallel claim pathways before the preemption bar arrives in each individual matter.
The lesson from Durnell for building new pesticide product liability cases is to lead with design defect and manufacturing defect theories alongside failure-to-warn, ensuring that the complaint articulates all three theories independently so that a successful preemption ruling on the labeling claim does not collapse the entire case. For case-building strategy on product defect theories in complex regulatory contexts, see the product liability archive. For broader context on how SCOTUS preemption rulings affect plaintiff strategy in medical device and pharmaceutical cases as well, see the case law and settlements section.